AST-to-platelet ratio as a prognostic factor in patients with decompensated liver cirrhosis

  • Marija Dukić Clinical Hospital Centre “Bezanijska kosa”, Gastroenterology and hepatology department, Belgrade, Serbia
  • Jovana Bogdanović Univerzitet u Beogradu, Medicinski fakultet, Srbija
  • Tijana Gmizić Clinical Hospital Centre “Bezanijska kosa”, Gastroenterology and hepatology department, Belgrade, Serbia
  • Marija Branković Clinical Hospital Centre “Bezanijska kosa”, Gastroenterology and hepatology department, Belgrade, Serbia; University of Belgrade, Faculty of Medicine, Serbia
DOI: https://doi.org/10.5937/mp76-55979
Keywords: decompensated liver cirrhosis, APRI score, AST, platelets, ethylism

Abstract


Introduction: Decompensated liver cirrhosis is a symtomatic, terminal stadium of liver cirrhosis, which occurs by the excange of healthy liver parenhime with fibrous tissue due to longterm inflamation. Many studies have been exploring the role of various factors in transition from stabile to decompensated liver cirrhosis. AST and platelet ratios (APRI score) turned up as a promising one to be further explored.

Aim: Our study aims to  determine if there is correlation between the APRI score and the prognosis of decompensated liver cirrhosis.

Material and Methods: A retrospective study was conducted in the Gastroenterology department in KBC „Bežanijska kosa“ in period from june 2022. to july 2023. This study includes 67 patients, about whom the data were collected from their medical history documents. All patients underwent comprenhensive biochemical blood analyses including hepatogram, and complete blood count upon admission. During hospitalization, abdominal ultrasound and esophagogastroduodenoscopy were also performed. For each patient, based on the available analysis results, the APRI score was calculated. All data were processed using the SPSS statistical program and presented graphically.

Results: Based on the results of logistic regression, we find that there is not enough evidence to consider the APRI score a significant predictor of mortailty in patients in this data set (p>0,05).

Conclusion: The APRI score can be significantly useful in everyday clinical practice for control and treatment of chronic inflammatory liver diseases, as it is an easily asccessible and a simple method. Further research is needed to explore and confirm its importance on a significantly larger dataset.

Keywords: decompensated liver cirrhosis, APRI score, AST, platelets, ethylism

References

1. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021; 398(10308):1359-1376.
2. Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019; 65:37-55.
3. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69(2):406–60.
4. Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 202; 75 Suppl 1(Suppl 1):S49S66.
5. Mansour D, McPherson S. Management of decompensated cirrhosis. Clin Med (Lond).
2018; 18(Suppl 2):s60-s65.
6. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2), 518–526.
7. Oikonomou T, Chrysavgis L, Kiapidou S, Adamantou M, Parastatidou D, Papatheodoridis GV, et al. Aspartate aminotransferase-to-platelet ratio index can predict the outcome in patients with stable decompensated cirrhosis. Ann Gastroenterol. 2023; 36(4):442448.
8. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726-36.
9. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013; 158:807-20.
10. Mao W, Sun Q, Fan J, Lin S, Ye B. AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis. Medicine (Baltimore). 2016; 95(9):e2946
11. Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008; 27(11):1017-29.
12. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig Dis Sci.
1988; 33(12):1601-14.
13. Sookoian S, Pirola CJ. Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine. World J Gastroenterol. 2015; 21(3):711-25.
14. Jepsen P, Younossi ZM. The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. J Hepatol. 2021;75 Suppl 1:S3-S13
Published
2025/12/19
Issue
Vol. 76 No. 4 (2025): Medicinski podmladak
Section
Original Scientific Paper